Free Access
Med Sci (Paris)
Volume 34, Number 1, Janvier 2018
Page(s) 12 - 14
Section Le Magazine
Published online 31 January 2018
  1. Calvayrac O, Pradines A, Pons E, et al. Molecular biomarkers for lung adenocarcinoma. Eur Respir J 2017; 49. pii: 1601734. [CrossRef] [PubMed] [Google Scholar]
  2. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. LancetOncol 2012; 13 : 239-46. [Google Scholar]
  3. Cortot AB, Janne PA. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev 2014; 23 : 356-66. [CrossRef] [PubMed] [Google Scholar]
  4. Faber AC, Corcoran RB, Ebi H, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011; 1 : 352-65. [CrossRef] [PubMed] [Google Scholar]
  5. de Bruin EC, Cowell C, Warne PH, et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov 2014; 4 : 606-19. [CrossRef] [PubMed] [Google Scholar]
  6. Tricker EM, Xu C, Uddin S, et al. Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov 2015; 5 : 960-71. [CrossRef] [PubMed] [Google Scholar]
  7. Hata AN, Niederst MJ, Archibald HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 2016; 22 : 262-9. [CrossRef] [PubMed] [Google Scholar]
  8. Ramirez M, Rajaram S, Steininger RJ, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun 2016; 7 : 10690. [CrossRef] [PubMed] [Google Scholar]
  9. Primeau M, Lamarche-Vane N. Coup d’œil sur les petites GTPases Rho. Med Sci (Paris) 2008; 24 : 15762. [Google Scholar]
  10. Mazieres J, Antonia T, Daste G, et al. Loss of RhoB expression in human lung cancer progression. Clin Cancer Res 2004; 10 : 2742-50. [CrossRef] [PubMed] [Google Scholar]
  11. Bousquet E, Calvayrac O, Mazieres J, et al. RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition. Oncogene 2016; 35 : 1760-9. [Google Scholar]
  12. Calvayrac O, Pradines A, Raymond-Letron I, et al. RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer. Clin Cancer Res 2014; 20 : 6541-50. [CrossRef] [PubMed] [Google Scholar]
  13. Calvayrac O, Mazieres J, Figarol S, et al. The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism. EMBO Mol Med 2017; 9 : 238-50. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.